• ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population
• First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies
• Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.